News
For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com
ICECURE’S PROSENSE® TUMOR FREEZING PRODUCT APPROVED FOR MARKET IN SOUTH AFRICA
Following IceCure’s accelerating global expansion, the company has received regulatory approval for the treatment of benign and cancerous tumors in many indications including for the
IceCure’s Global Expansion Accelerates; Tumor Freezing Product Now Approved for Market in India
New Indian regulatory approval received for its cryoablation technology to destroy tumors in extensive indications, including for breast, lung, bone and kidney cancer. Read more.
IceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement with MTS Medical Technology
New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors. Read more.
IceCure Continues Global Expansion to Freeze Tumors
New Territory in Singapore with Global Medical Leader, Terumo, Marks Successful Partnership Progress in Executing Milestone Distribution Agreement. Read more
IceCure Medical Continues Expansion in Asia; Receives Largest Purchase Order for ProSense™ Cryoablation System
Healthcare Institutions Continue to Adopt Minimally Invasive Oncology Solutions to Address Growing Demand and Provide Clinical and Economic Benefits. Read more
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS APRIL 2, 2020
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure, to be held on Thursday, April 2, 2020, at
ICECURE’S PROSENSE® TUMOR FREEZING PRODUCT APPROVED FOR MARKET IN SOUTH AFRICA
Following IceCure’s accelerating global expansion, the company has received regulatory approval for the treatment of benign and cancerous tumors in many indications including for the
IceCure’s Global Expansion Accelerates; Tumor Freezing Product Now Approved for Market in India
New Indian regulatory approval received for its cryoablation technology to destroy tumors in extensive indications, including for breast, lung, bone and kidney cancer. Read more.
IceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement with MTS Medical Technology
New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors. Read more.
IceCure Continues Global Expansion to Freeze Tumors
New Territory in Singapore with Global Medical Leader, Terumo, Marks Successful Partnership Progress in Executing Milestone Distribution Agreement. Read more
IceCure Medical Continues Expansion in Asia; Receives Largest Purchase Order for ProSense™ Cryoablation System
Healthcare Institutions Continue to Adopt Minimally Invasive Oncology Solutions to Address Growing Demand and Provide Clinical and Economic Benefits. Read more
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS APRIL 2, 2020
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure, to be held on Thursday, April 2, 2020, at